ArticleScience advances2024
Upconversion dual-photosensitizer-expressing bacteria for near-infrared monochromatically excitable synergistic phototherapy.
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 56 citations in OpenAlex.
- BiohybridMaterials today. Bio · 2026Article
- Living Inorganic Nanomaterials: Design, Preparation, and Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine.Journal of hematology & oncology · 2026Review
- Polysaccharide-Based Encapsulation of Microbes for Enhanced Microbial Therapy.Polymer science & technology (Washington, D.C.) · 2026Review
- Development of bacterial sonosensitizer hybrid systems to enhance cancer sono-immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Photoactivated probiotic micro-reactor synchronizes STING/TLRs agonists to spatiotemporally synergize antitumor immunotherapy.Journal of nanobiotechnology · 2026Article
- From Mechanism to Clinic: Engineered Bacteria-Nanomaterial Hybrid Systems for Cancer Immunotherapy.Research (Washington, D.C.) · 2026Article
- Oral delivery of aptamer-decorated SICTERS Raman probes for colonoscopy-guided resection and photothermal immunization of microtumors.Science advances · 2025Article
- Recent Advances in Nanoparticle-Mediated Antibacterial Photodynamic Therapy.International journal of molecular sciences · 2025Review
- Enabling highly efficient infrared silicon photodetectors via disordered metasurfaces with upconversion nanoparticles.Science advances · 2025Article
- Biocompatible cloaking of bacteria for effective tumor imaging and therapy.Materials today. Bio · 2025Article
- Targeting the Adenosine-Mediated Metabolic Immune Checkpoint with Engineered Probiotic for Enhanced Chemo-Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Resynthesis of synthetic biology techniques: combining engineered bacteria with other antitumour therapies.Frontiers in microbiology · 2025Review
- Rapid and Large-Scale Synthesis of Chiral and Fluorescent Sulfur Quantum Dots for Intracellular Temperature Monitoring.Chemical & biomedical imaging · 2024Article
- A hypoxia-activated and microenvironment-remodeling nanoplatform for multifunctional imaging and potentiated immunotherapy of cancer.Nature communications · 2024Article
- Colon-specific controlled release of oral liposomes for enhanced chemo-immunotherapy against colorectal cancer.Acta pharmaceutica Sinica. B · 2024Article
- Genetically Designed Living Bacteria with Melanogenesis for Tumor-Specific Pigmentation and Therapeutic Intervention.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- NIR light-activated nanocomposites combat biofilm formation and enhance antibacterial efficacy for improved wound healing.Communications chemistry · 2024Article
- NaYFMikrochimica acta · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synergistic phototherapy stands for superior treatment prospects than a single phototherapeutic modality. However, the combined photosensitizers often suffer from incompatible excitation mode, limited irradiation penetration depth, and lack of specificity. We describe the development of upconversion dual-photosensitizer-expressing bacteria (UDPB) for near-infrared monochromatically excitable combination phototherapy. UDPB are prepared by integrating genetic engineering and surface modification, in which bacteria are encoded to simultaneously express photothermal melanin and phototoxic KillerRed protein and the surface primary amino groups are derived to free thiols for biorthogonal conjugation of upconversion nanoparticles. UDPB exhibit a near-infrared monochromatic irradiation-mediated dual-activation characteristic as the photothermal conversion of melanin can be initiated directly, while the photodynamic effect of KillerRed can be stimulated indirectly by upconverted visible light emission. UDPB also show living features to colonize hypoxic lesion sites and inhibit pathogens via bacterial community competition. In two murine models of solid tumor and skin wound infection, UDPB separately induce robust antitumor response and a rapid wound healing effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.